Endocrinology · Hypoparathyroidism

Standard of Care: Managing Calcium and Protecting Your Kidneys

At a Glance

The standard of care for hypoparathyroidism involves balancing blood calcium at a 'low-normal' level (8.0-9.0 mg/dL) to prevent symptoms while avoiding kidney damage. Treatment typically requires active vitamin D (calcitriol) and oral calcium, or PTH replacement therapy for severe cases.

The goal of managing impaired PTH secretion is not just to “fix” a number on a lab report, but to strike a delicate balance. Your care team aims to keep your calcium high enough to prevent symptoms like tingling and cramps, but low enough to protect your kidneys from long-term damage ^[1]^[2].

The First-Line Approach: Functional Causes

If your impaired PTH secretion is functional (caused by low magnesium), the order of operations is critical. Replacing magnesium is the absolute first step ^[3].

Calcium and vitamin D treatments will not work properly if your body is severely depleted of magnesium ^[3]. Once magnesium is restored, the parathyroid glands usually “wake up” and resume producing PTH within days to weeks, meaning you likely won’t need lifelong calcium therapy ^[4]^[5].

The First-Line Approach: Chronic Causes

For patients with permanent parathyroid damage (such as from surgery), the “gold standard” treatment is a combination of oral supplements that do the work your PTH can no longer do ^[6]. This typically includes:

Oral Calcium: Often taken in several smaller doses throughout the day to ensure steady absorption ^[7]. Note that calcium carbonate must be taken with food to be properly absorbed, whereas calcium citrate can be taken on an empty stomach ^[6].
Active Vitamin D (Calcitriol): Standard Vitamin D (from the sun or a multivitamin) must be activated by the kidneys—a process that requires PTH ^[8]. Because you lack enough PTH, you must take the “pre-activated” form, calcitriol, so your body can actually use it to absorb calcium ^[6]^[9].

Aiming for “Low-Normal”

In healthy people, the body tightly regulates calcium. Without PTH, the body loses its ability to “reclaim” calcium from the kidneys ^[10]. If your blood calcium is pushed too high, the excess “spills” into your urine, which can cause kidney stones or kidney damage ^[11]^[12].

Because of this, the therapeutic target is usually a low-normal calcium level—typically between 8.0 and 9.0 mg/dL (2.00–2.25 mmol/L) ^[1]^[13].

Specialized Tools: Thiazide Diuretics

Medications like hydrochlorothiazide (HCTZ) are often used for blood pressure, but in hypoparathyroidism, they have a special purpose ^[14]. They help the kidneys reabsorb calcium back into the blood, which lowers the amount of calcium in your urine and protects your kidneys from damage ^[15]^[16].

Advanced Options: PTH Replacement Therapy

For some patients with chronic hypoparathyroidism, conventional therapy isn’t enough. They may still have severe symptoms, or their urine calcium levels may remain dangerously high despite treatment ^[17]^[18]. In these refractory cases, doctors may use hormone replacement therapy.

Note: In the past, a drug called rhPTH(1-84) (Natpara) was used, but it has been recalled and is being globally discontinued by its manufacturer ^[19].

Today, the focus is on newer options like palopegteriparatide, a long-acting replacement for PTH that helps stabilize calcium levels throughout the day ^[20]^[21]. These therapies aim to mimic the body’s natural PTH more closely, potentially improving quality of life and reducing the long-term risk of kidney impairment ^[22]^[23].

Common questions in this guide

What is the target calcium level for hypoparathyroidism?

Doctors typically aim for a 'low-normal' blood calcium level, usually between 8.0 and 9.0 mg/dL. This delicate balance helps prevent symptoms of low calcium, like muscle cramps, while protecting your kidneys from long-term damage and kidney stones.

Why do I need to take calcitriol instead of regular vitamin D?

Standard vitamin D needs to be activated by the kidneys, a process that requires parathyroid hormone (PTH). Because you lack enough PTH, you must take calcitriol, which is already active and directly helps your body absorb calcium.

How does magnesium affect my parathyroid condition?

Severe magnesium deficiency can stop your parathyroid glands from working properly, causing functional hypoparathyroidism. Restoring magnesium levels often allows the glands to 'wake up' and resume producing PTH normally again.

Why are thiazide diuretics used for hypoparathyroidism?

Medications like hydrochlorothiazide help your kidneys reabsorb calcium back into the blood rather than losing it. This lowers the amount of calcium in your urine, reducing the risk of kidney stones and long-term kidney damage.

What happens if standard calcium treatments don't work?

If oral calcium and calcitriol aren't controlling your symptoms or if urine calcium remains dangerously high, you may be a candidate for PTH replacement therapies. Newer options like palopegteriparatide can help stabilize calcium levels throughout the day.

Curated prompts to bring to your next appointment.

1.Given my specific lab results, what is our exact target range for my serum calcium?
2.Would adding a thiazide diuretic like hydrochlorothiazide help lower my 24-hour urine calcium and protect my kidneys?
3.Am I a candidate for PTH replacement therapy like palopegteriparatide if my calcium levels remain unstable?
4.How does my magnesium level affect the effectiveness of the calcitriol I'm taking?
5.If my condition is functional, how should we taper my calcium and vitamin D once my magnesium is corrected?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (23)

1
Association of Serum Calcium and Phosphate With Incident Cardiovascular Disease in Patients With Hypoparathyroidism.
Kaul S, Ayodele O, Chen K, et al.
The American journal of cardiology 2023; (194()):60-70 doi:10.1016/j.amjcard.2023.01.029.
PMID: 36989548
2
Hypoparathyroidism: update of guidelines from the 2022 International Task Force.
Clarke BL
Archives of endocrinology and metabolism 2022; (66(5)):604-610.
PMID: 36382749
3
Proton pump inhibitor-induced hypomagnesemia, a rare cause of reversible delirium: A case report with literature review.
Zhao W, Zhang J, Jia H, et al.
Medicine 2024; (103(40)):e39729 doi:10.1097/MD.0000000000039729.
PMID: 39465769
4
Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia.
Majumder A, Basu S
Journal of the ASEAN Federation of Endocrine Societies 2020; (35(1)):129-132 doi:10.15605/jafes.035.01.23.
PMID: 33442182
5
Suppression of Parathyroid Hormone in a Patient with Severe Magnesium Depletion.
Mutnuri S, Fernandez I, Kochar T
Case reports in nephrology 2016; (2016()):2608538 doi:10.1155/2016/2608538.
PMID: 27190662
6
Challenges in the management of chronic hypoparathyroidism.
Zavatta G, Clarke BL
Endocrine connections 2020; (9(10)):R229-R240.
PMID: 33486471
7
Identifying Clinical Characteristics of Hypoparathyroidism in Turkey: HIPOPARATURK-NET Study.
Konca Degertekin C, Gogas Yavuz D, Pekkolay Z, et al.
Calcified tissue international 2022; (110(2)):204-214 doi:10.1007/s00223-021-00908-2.
PMID: 34495356
8
Physiology of Parathyroid Hormone.
Goltzman D
Endocrinology and metabolism clinics of North America 2018; (47(4)):743-758 doi:10.1016/j.ecl.2018.07.003.
PMID: 30390810
9
Parathyroid Hormone Replacement versus Oral Calcium and Active Vitamin D Supplementation in Hypoparathyroidism: A Meta-analysis.
Palui R, Das RR, Roy A, et al.
Indian journal of endocrinology and metabolism 2020; (24(2)):206-214 doi:10.4103/ijem.IJEM_579_19.
PMID: 32699792
10
Conventional Treatment of Hypoparathyroidism.
Marcucci G, Brandi ML
Frontiers of hormone research 2019; (51()):160-164 doi:10.1159/000491046.
PMID: 30641530
11
Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism.
Gosmanova EO, Houillier P, Rejnmark L, et al.
Reviews in endocrine & metabolic disorders 2021; (22(2)):297-316 doi:10.1007/s11154-020-09613-1.
PMID: 33599907
12
Incident comorbidities in patients with chronic hypoparathyroidism after thyroidectomy: a multicenter nationwide study.
Díez JJ, Anda E, Pérez-Corral B, et al.
Frontiers in endocrinology 2024; (15()):1348971 doi:10.3389/fendo.2024.1348971.
PMID: 38481445
13
[CME: Hypocalcemia and Hypoparathyroidism].
Burget L
Praxis 2021; (110(13)):703-708 doi:10.1024/1661-8157/a003751.
PMID: 34583536
14
[Differential diagnosis of normocalcemic hyperparathyroidism and idiopathic hypercalciuria on the example of clinical case].
Runova GE, Golounina OO, Glinkina IV, et al.
Problemy endokrinologii 2020; (66(6)):13-17 doi:10.14341/probl12677.
PMID: 33481363
15
Hydrochlorothiazide with salt restriction in nonsurgical hypoparathyroidism: a placebo-controlled single-blinded randomized crossover trial assessing efficacy and safety.
Jha V, Mukherjee S, Bhadada SK, et al.
JBMR plus 2025; (9(12)):ziaf174 doi:10.1093/jbmrpl/ziaf174.
PMID: 41293325
16
Cracking the natriuresis puzzle: Insight from structural biology.
Tian XY, Wong WT, Zhu Z
Med (New York, N.Y.) 2023; (4(4)):223-225 doi:10.1016/j.medj.2023.03.004.
PMID: 37060898
17
[Hypoparathyroidism - un underestimated problem?]
Petersenn S, Bojunga J, Brabant G, et al.
MMW Fortschritte der Medizin 2019; (161(Suppl 7)):12-20 doi:10.1007/s15006-019-1174-4.
PMID: 31828671
18
A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides.
Marcucci G, Brandi ML
Frontiers of hormone research 2019; (51()):165-171 doi:10.1159/000491047.
PMID: 30641529
19
Hypoparathyroidism: diagnosis, management and emerging therapies.
Khan S, Khan AA
Nature reviews. Endocrinology 2025; (21(6)):360-374 doi:10.1038/s41574-024-01075-8.
PMID: 39905273
20
Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA).
Díez JJ, Badia X, Abad R, et al.
Advances in therapy 2025; (42(12)):6234-6247 doi:10.1007/s12325-025-03396-0.
PMID: 41134515
21
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial.
Rubin MR, Clarke BL, Hofbauer LC, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2026; doi:10.1093/jbmr/zjag013.
PMID: 41636590
22
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.
Clarke BL, Khan AA, Rubin MR, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(4)):951-960 doi:10.1210/clinem/dgae693.
PMID: 39376010
23
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
Khan AA, Rejnmark L, Rubin M, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(1)):e372-e385 doi:10.1210/clinem/dgab577.
PMID: 34347093

This page provides educational information about managing hypoparathyroidism and calcium levels. Always consult your endocrinologist or healthcare team for personalized medical advice.

Get notified when new evidence is published on Secondary hypoparathyroidism due to impaired parathormon secretion.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents